1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,212 | 0,236 | 23:00 | |
| 0,216 | 0,234 | 21:37 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:54 | Brii Biosciences reports 1H results | 1 | Seeking Alpha | ||
| 12:02 | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results | 33 | PR Newswire | Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy
Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic... ► Artikel lesen | |
| 12:00 | BRII-B (02137): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
| 11.08. | BRII-B (02137): DATE OF BOARD MEETING | 1 | HKEx | ||
| 04.07. | Brii Biosciences and Joincare sign licence agreement for BRII-693 | 1 | Pharmaceutical Technology | ||
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 04.07. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT LICENSE AGREEMENT WITH JOINCARE | 2 | HKEx | ||
| 03.06. | BRII-B (02137): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 03.06. | BRII-B (02137): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 3, 2025 AND CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 08.05. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | 1 | HKEx | ||
| 28.04. | BRII-B (02137): CLARIFICATION ANNOUNCEMENT (1) CHANGE OF DATE OF ANNUAL GENERAL MEETING; AND (2) CHANGE OF CLOSURE OF THE REGISTER OF MEMBERS | 1 | HKEx | ||
| 25.04. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 25.04. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
| 25.04. | BRII-B (02137): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 25.04. | BRII-B (02137): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 25.04. | BRII-B (02137): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 25.04. | BRII-B (02137): (1) PROPOSALS FOR ADOPTION OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS; (2) RE-ELECTION OF RETIRING DIRECTORS; (3) RE-APPOINTMENT ... | - | HKEx | ||
| 25.04. | BRII-B (02137): 2024 ANNUAL REPORT | - | HKEx | ||
| 07.04. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 30.03. | Brii Biosciences Limited: Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification | 74 | PR Newswire | Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and... ► Artikel lesen | |
| 21.03. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results | 286 | PR Newswire | Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure
Data... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 119,60 | +0,25 % | Leichte Zugewinne bei der Biogen-Aktie (118,75 €) | Im Plus liegt derzeit die Biogen-Aktie . Zuletzt zahlten Investoren für das Wertpapier 118,75 Euro. An der US-amerikanischen Börse hat sich heute die Aktie von Biogen zwischenzeitlich um 1,93 Prozent... ► Artikel lesen | |
| ILLUMINA | 86,69 | +0,24 % | Die Demo zu Pokémon-Legenden: Z-A zeigt interessante Details zur Map von Illumina City | ||
| NANOREPRO | 2,000 | +21,58 % | Original-Research: NanoRepro AG (von GBC AG): Kaufen | Original-Research: NanoRepro AG - von GBC AG
19.08.2025 / 10:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
| BRAIN BIOTECH | 2,070 | +2,48 % | EQS-News: BRAIN Biotech AG: Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Personalie
Erfahrene Biotechnologie-Expertin neu im Aufsichtsrat der BRAIN Biotech AG
23.07.2025 / 08:30 CET/CEST
Für den... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,620 | -0,96 % | BioNxt: Mit Adipositas-Medikament ohne Spritze zum Erfolg | Seit August 2019 ist die BioNxt-Aktie (0,64 EUR; WKN: A3D1K3; ISIN: CA0909741062) nun an den deutschen Börsen gelistet. Anfangs als hoffnungsvoller Cannabis-Wert gestartet, zeigt sich das Unternehmen... ► Artikel lesen | |
| INFLARX | 0,754 | -1,31 % | InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,379 | +2,71 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,540 | -7,78 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 First Quarter Results | Vancouver, British Columbia--(Newsfile Corp. - August 13, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| TME PHARMA | 0,097 | +0,41 % | TME Pharma N.V.: TME Pharma Provides Update About Additional Strategy | Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased... ► Artikel lesen | |
| CYTODYN | 0,240 | +3,45 % | CytoDyn Inc.: CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab | Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal... ► Artikel lesen | |
| IMMUNIC | 0,802 | +2,30 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07.08.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,070 | +2,99 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,203 | +1,66 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Receives Health Canada Approval for Advanced Melanoma | First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen |
BRII BIOSCIENCES LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,220 Euro und damit -4,35 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.